Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 1/20 | 0.42 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL658277 | 0.86 | EPHX2 (0.44) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| SCHEMBL1073942 | 0.76 | EPHX2 (0.45) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| SCHEMBL1677868 | 0.74 | EPHX2 (0.41) | SLC22A2SLC47A1MAPTEPHX2MEN1 | |
| SCHEMBL658693 | 0.74 | SLC22A2 (0.40) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| SCHEMBL660251 | 0.74 | SLC22A2 (0.52) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL1677812 | 0.73 | EPHX2 (0.40) | SLC22A2SLC47A1MAPTEPHX2MEN1 | |
| Hydrochloric Acid SCHEMBL1677957 | 0.72 | MAPT (0.54) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| SCHEMBL1981155 | 0.72 | EPHX2 (0.51) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| SCHEMBL136083 | 0.71 | SLC22A2 (0.48) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| SCHEMBL5261666 | 0.69 | GRIN2D (0.41) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453017-B2 | Antiviral therapies with phospholipase D inhibitors | VANDERBILT UNIVERSITY (US) | 2016-09-27 | — | — | US | claimed |
| US-20120157537-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | IQBAL KHALID (US) | 2012-06-21 | — | — | US | claimed |
| US-20090124659-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-05-14 | — | — | US | claimed |
| US-20090005459-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | IQBAL KHALID | 2009-01-01 | — | — | US | claimed |
| EP-1838297-A1 | 1-AMINOCYCLOHEXANE-DERIVATIVES FOR THE TREATMENT OF MULTIPLE SCLEROSIS EMOTIONAL LABILITY AND PSEUDOBULBAR AFFECT | Merz Pharma GmbH & Co. KGaA (DE) | 2007-10-03 | — | — | EP | claimed |
| US-20060205822-A1 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect | FOREST LABORATORIES, INC. (US) | 2006-09-14 | — | — | US | claimed |
| WO-2006069294-A1 | 1-AMINOCYCLOHEXANE-DERIVATIVES FOR THE TREATMENT OF MULTIPLE SCLEROSIS EMOTIONAL LABILITY AND PSEUDOBULBAR AFFECT | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-06-29 | — | — | WO | claimed |
| EP-1556019-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | Merz Pharma GmbH & Co. KGaA (DE) | 2005-07-27 | — | — | EP | claimed |
| US-20050113458-A1 | delivering to said cell an 1-aminocyclohexane derivative; for decreasing the level of at least one amyloid peptide produced by a mammalian cell that expresses amyloid precursor protein | FOREST LABORATORIES, INC. (US) | 2005-05-26 | — | — | US | claimed |
| EP-1523309-A2 | NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN TAU | Iqbal, Khalid (US) | 2005-04-20 | — | — | EP | claimed |
| WO-2004037234-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | WO | claimed |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | US | claimed |
| WO-2004009062-A2 | NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau | IQBAL KHALID (US) | 2004-01-29 | — | — | WO | claimed |
| US-20040019118-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | IQBAL KHALID (US) | 2004-01-29 | — | — | US | claimed |
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO KGAA (DE) | 2021-06-10 | — | — | US | disclosed |
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | UNIV VANDERBILT (US) | 2017-11-09 | — | — | US | disclosed |
| US-9453017-B2 | Antiviral therapies with phospholipase D inhibitors | VANDERBILT UNIVERSITY (US) | 2016-09-27 | — | — | US | disclosed |
| WO-2004037234-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | WO | disclosed |
| US-20040019118-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | IQBAL KHALID (US) | 2004-01-29 | — | — | US | disclosed |
| US-5061703-A | ALZHEIMER*S DISEASE | MERZ + CO. GMBH & CO. (DE) | 1991-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157537-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | GRIN1, GRIN2A, MAPT | SLC22A2 2324/4885SLC47A1 2325/4885MAPT 3/4885 |
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, PSEN1, BCHE | SLC22A2 1069/4885SLC47A1 1391/4885MAPT 53/4885 |
| US-20090005459-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | GRIN1, GRIN2A, MAPT | SLC22A2 2324/4885SLC47A1 2325/4885MAPT 3/4885 |
| US-20040019118-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | GRIN2A, GRIN1, MAPT | SLC22A2 1805/4885SLC47A1 2398/4885MAPT 3/4885 |
| US-20090124659-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors | ACHE, BACE1, BCHE | SLC22A2 2056/4885SLC47A1 1733/4885MAPT 162/4885 |
| US-20050113458-A1 | delivering to said cell an 1-aminocyclohexane derivative; for decreasing the level of at least one amyloid peptide produced by a mammalian cell that expresses amyloid precursor protein | APP, BACE1, PSEN1 | SLC22A2 1054/4885SLC47A1 76/4885MAPT 42/4885 |
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | PLD1, PLD2, PIK3CD | SLC22A2 4447/4885SLC47A1 2610/4885MAPT 3179/4885 |
| US-20060205822-A1 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect | NMBR, NMUR1, CNR1 | SLC22A2 2261/4885SLC47A1 1872/4885MAPT 328/4885 |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | ACHE, BACE1, CHRNA5 | SLC22A2 1893/4885SLC47A1 1560/4885MAPT 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.